// App-Quantinova.ai

3033 : Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkins Lymphomas

Researchers

Presenter

  • Fredrick B. Hagemeister

Principal Investigators

  • Maria Alma Rodriguez

  • Steven R. Deitcher

  • Felipe Samaniego

  • Jeffrey A. Silverman

  • Andreas H. Sarris

  • Fernando Cabanillas

  • Anas Younes

  • Luis Fayad

  • Andre Goy

  • Nam H. Dang

  • A Forman

  • Peter McLaughlin

  • Barbara Pro

  • Jorge Enrique Romaguera

Medical Centers

  • Medicine, Division of Hematology/Oncology, University of Florida Shands Cancer Center, Gainesville, FL

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Dept of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Euroclinic, Athens, Greece

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Auxilio Mutuo Cancer Center, San Juan, PR

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

Locations

  • United States

  • Greece

Companies

  • Talon Therapeutics,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Acute lymphoblastic leukemia

  • B-Cell Non-Hodgkin Lymphoma

  • Peripheral neuropathy

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Constipation

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Vincristine

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Doxorubicin

  • Prednisone

  • Rituximab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved